Telomir Pharmaceuticals (NASDAQ: TELO) has announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that its lead compound, Telomir-Zn, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson's disease model. The study showed that Telomir-Zn reduced oxidative stress, lowered hepatic copper burden, and improved liver function markers, supporting its biological activity in Wilson's disease.
Wilson's disease is a genetic disorder characterized by excessive copper accumulation in the body, primarily affecting the liver and brain. Current treatments focus on copper chelation or zinc supplementation to reduce copper absorption. The preclinical findings suggest Telomir-Zn could offer a novel therapeutic approach by modulating intracellular metal homeostasis and redox balance.
The publication expands the scientific validation for Telomir-Zn, which is also being advanced as a potential treatment for triple-negative breast cancer. The company is preparing to initiate a Phase 1/2 clinical trial for its lead oncology program. According to the press release, the data underscore Telomir-Zn's ability to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics. Telomir-Zn has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
For more details, the full press release is available at https://ibn.fm/fOSNo. Additional updates on TELO can be found in the company's newsroom at https://ibn.fm/TELO.
